12/4
10:31 am
crsp
Cathie Wood's Buys And Rumors Aside, Here's Why Crispr Therapeutics Is A Strong Buy [Seeking Alpha]
Low
Report
Cathie Wood's Buys And Rumors Aside, Here's Why Crispr Therapeutics Is A Strong Buy [Seeking Alpha]
12/2
02:16 pm
crsp
CRISPR Therapeutics: CTX310 De-Risks, CASGEVY Disappoints Amid Takeover Rumors [Seeking Alpha]
Low
Report
CRISPR Therapeutics: CTX310 De-Risks, CASGEVY Disappoints Amid Takeover Rumors [Seeking Alpha]
12/1
05:37 am
crsp
What CRISPR Therapeutics' (CRSP) Latest Trial Results Mean for Investors [Yahoo! Finance]
Low
Report
What CRISPR Therapeutics' (CRSP) Latest Trial Results Mean for Investors [Yahoo! Finance]
11/29
04:21 pm
crsp
CRISPR Therapeutics (CRSP): Assessing Valuation in Light of Recent Share Price Volatility [Yahoo! Finance]
Medium
Report
CRISPR Therapeutics (CRSP): Assessing Valuation in Light of Recent Share Price Volatility [Yahoo! Finance]
11/29
01:13 pm
crsp
Citizens Maintains Market Outperform on CRISPR Therapeutics (CRSP) Despite Casgevy Slowdown [Yahoo! Finance]
Medium
Report
Citizens Maintains Market Outperform on CRISPR Therapeutics (CRSP) Despite Casgevy Slowdown [Yahoo! Finance]
11/26
07:02 am
crsp
CRISPR Therapeutics (NASDAQ:CRSP) was given a new $74.00 price target on by analysts at Chardan Capital.
Low
Report
CRISPR Therapeutics (NASDAQ:CRSP) was given a new $74.00 price target on by analysts at Chardan Capital.
11/25
08:51 am
crsp
Oppenheimer Reaffirms Outlook on CRISPR Therapeutics (CRSP) After Encouraging Q3 Earnings Performance [Yahoo! Finance]
Medium
Report
Oppenheimer Reaffirms Outlook on CRISPR Therapeutics (CRSP) After Encouraging Q3 Earnings Performance [Yahoo! Finance]
11/19
07:38 pm
crsp
This Leading Gene-Editing Stock Could Be Going Private. Should You Buy Its Shares First? [Yahoo! Finance]
Medium
Report
This Leading Gene-Editing Stock Could Be Going Private. Should You Buy Its Shares First? [Yahoo! Finance]
11/19
01:42 pm
crsp
RBC Capital Lifts CRISPR Therapeutics (CRSP) Target to $50, Keeps Sector Perform [Yahoo! Finance]
Low
Report
RBC Capital Lifts CRISPR Therapeutics (CRSP) Target to $50, Keeps Sector Perform [Yahoo! Finance]
11/19
11:28 am
crsp
The Biotech Sector is Seeing a Major Boost From Programmable Cell Therapies in Chronic Disease Care [Canadian Business Journal (Canada)]
Low
Report
The Biotech Sector is Seeing a Major Boost From Programmable Cell Therapies in Chronic Disease Care [Canadian Business Journal (Canada)]
11/17
12:23 am
crsp
Positive CTX310 Phase 1 Results Might Change The Case For Investing In CRISPR Therapeutics (CRSP) [Yahoo! Finance]
Medium
Report
Positive CTX310 Phase 1 Results Might Change The Case For Investing In CRISPR Therapeutics (CRSP) [Yahoo! Finance]
11/14
07:08 pm
crsp
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know [Yahoo! Finance]
Medium
Report
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know [Yahoo! Finance]
11/11
08:28 am
crsp
Evox Therapeutics Appoints Douglas Treco, Ph.D., to Board of Directors [Yahoo! Finance]
Low
Report
Evox Therapeutics Appoints Douglas Treco, Ph.D., to Board of Directors [Yahoo! Finance]
11/11
08:16 am
crsp
CRISPR Therapeutics (NASDAQ:CRSP) had its price target lowered by analysts at Robert W. Baird from $52.00 to $44.00. They now have a "neutral" rating on the stock.
Low
Report
CRISPR Therapeutics (NASDAQ:CRSP) had its price target lowered by analysts at Robert W. Baird from $52.00 to $44.00. They now have a "neutral" rating on the stock.
11/11
07:03 am
crsp
CRISPR Therapeutics (NASDAQ:CRSP) had its "sector perform" rating reaffirmed by analysts at Royal Bank Of Canada.
Low
Report
CRISPR Therapeutics (NASDAQ:CRSP) had its "sector perform" rating reaffirmed by analysts at Royal Bank Of Canada.
11/11
06:02 am
crsp
CRISPR Therapeutics (NASDAQ:CRSP) had its "market outperform" rating reaffirmed by analysts at Citigroup Inc..
Low
Report
CRISPR Therapeutics (NASDAQ:CRSP) had its "market outperform" rating reaffirmed by analysts at Citigroup Inc..
11/10
12:06 pm
crsp
CRISPR Therapeutics (NASDAQ:CRSP) had its price target lowered by analysts at Needham & Company LLC from $81.00 to $80.00. They now have a "buy" rating on the stock.
Low
Report
CRISPR Therapeutics (NASDAQ:CRSP) had its price target lowered by analysts at Needham & Company LLC from $81.00 to $80.00. They now have a "buy" rating on the stock.
11/10
08:18 am
crsp
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results [Yahoo! Finance]
Medium
Report
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results [Yahoo! Finance]
11/10
08:13 am
crsp
CRISPR Therapeutics GAAP EPS of -$1.17 beats by $0.07, revenue of $0.89M [Seeking Alpha]
Medium
Report
CRISPR Therapeutics GAAP EPS of -$1.17 beats by $0.07, revenue of $0.89M [Seeking Alpha]
11/10
08:00 am
crsp
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results
Medium
Report
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results
11/8
10:11 am
crsp
CRISPR Therapeutics Announces Positive Phase 1 Clinical Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and Lipid Lowering [Yahoo! Finance]
Low
Report
CRISPR Therapeutics Announces Positive Phase 1 Clinical Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and Lipid Lowering [Yahoo! Finance]
11/8
09:56 am
crsp
CRISPR Therapeutics Announces Positive Phase 1 Clinical Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and Lipid Lowering
Low
Report
CRISPR Therapeutics Announces Positive Phase 1 Clinical Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and Lipid Lowering
11/7
05:02 pm
crsp
Australia's Monash University Bets Big On Global Innovation [Forbes]
Low
Report
Australia's Monash University Bets Big On Global Innovation [Forbes]
11/6
09:23 am
crsp
CRISPR Therapeutics (NASDAQ:CRSP) had its price target lowered by analysts at Wedbush from $13.00 to $9.00. They now have an "outperform" rating on the stock.
Low
Report
CRISPR Therapeutics (NASDAQ:CRSP) had its price target lowered by analysts at Wedbush from $13.00 to $9.00. They now have an "outperform" rating on the stock.
10/24
08:10 pm
crsp
A Look at CRISPR Therapeutics's Valuation Following New CTX460 Gene Editing Breakthrough Data [Yahoo! Finance]
Low
Report
A Look at CRISPR Therapeutics's Valuation Following New CTX460 Gene Editing Breakthrough Data [Yahoo! Finance]